A personalized vaccine for melanoma cut the risk of cancer returning after five years

An experimental vaccine from Moderna shows promise in keeping deadly skin cancer from returning for years, according to new clinical trial results.

An experimental vaccine from Moderna shows promise in keeping deadly skin cancer from returning for years, according to new clinical trial results.

Subscribe to read this story ad-free

Get unlimited access to ad-free articles and exclusive content.

The research, presented Monday at the American Society of Clinical Oncology’s annual meeting, found that a personalized mRNA vaccine halved the risk of melanoma returning after five years. The results were also published in the Journal of Clinical Oncology.

Melanoma is the deadliest form of skin cancer, and in about half of patients, the disease will come back within the first five years of treatment.